Mavacamten therapy significantly improved diastolic function and LA remodeling over 24 months in HCM patients, including a decrease in LAVI from 42.2 to 30.2 mL/m2 (p<0.001).
Cohort (n=51)
Does mavacamten improve echocardiographic measures of diastolic function and cardiac structure in adults with hypertrophic cardiomyopathy?
In a real-world cohort of patients with hypertrophic cardiomyopathy, long-term treatment with mavacamten was associated with sustained improvements in echocardiographic measures of diastolic function and cardiac reverse remodeling over 24 months.
p-value: p=<0.001
Diastolic dysfunction is a key determinant of symptoms and adverse remodeling in hypertrophic cardiomyopathy (HCM).Data describing the durability of diastolic improvement with long-term cardiac myosin inhibitor therapy in real-world settings remain limited.We performed a real-world cohort study of adults with HCM treated with at least 18 months of mavacamten with serial echocardiography at approximately 3month intervals through 24 months.LV structure, standard diastolic indices and diastolic dysfunction grade were assessed.Paired baseline and end-point measures were compared.Fifty-one patients were included (mean age 58 14 years; 45% men).From baseline to 24 months, LAVI decreased from 42.2 14.4 to 30.2 11.7 mL/m ( -12.0, p<0.001);LV wall thickness decreased from 18.7 3.0 to 15.2 2.3 mm ( -3.5, p<0.001); and LV mass index decreased from 121.6 33.5 to 98.1 22.3 g/m ( -23.4,p<0.001).Lateral e increased from 0.08 0.03 to 0.09 0.03 m/s (p<0.001) and medial e increased from 0.05 0.02 to 0.07 0.02 m/s (p<0.001).Lateral E/e decreased from 14.3 8.9 to 9.8 3.9 (p<0.001) and medial E/e decreased from 18.8 11.3 to 13.3 4.7 (p<0.001).RVSP decreased from 30.0 12.0 to 26.5 8.9 mmHg (p=0.01).Diastolic dysfunction grade distribution shifted toward lower grades over time.In conclusion, in a real-world HCM cohort treated with mavacamten, echocardiographic measures of diastolic function, LA remodeling, and pulmonary pressures improved and remained durable through 24 months
Bavishi et al. (Wed,) conducted a cohort in Hypertrophic cardiomyopathy (n=51). Mavacamten vs. Baseline was evaluated on Echocardiographic measures of LV structure and diastolic function (p=<0.001). Mavacamten therapy significantly improved diastolic function and LA remodeling over 24 months in HCM patients, including a decrease in LAVI from 42.2 to 30.2 mL/m2 (p<0.001).